Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Novartis discloses EZH2 and EED inhibitors

March 7, 2022

Medshine Discovery identifies new BRD4 inhibitors

March 7, 2022

Shenzhen Chipscreen Biosciences discloses new PTPN11 inhibitors

March 7, 2022

Engineered retinal cells stare daggers at peritoneal tumors

March 4, 2022

Phenanthroline derivative with antitumor activity in liver cancer models

March 4, 2022

Cornell University patents PROTACs targeting BET domain proteins

March 4, 2022

New prodrugs of PIN1 inhibitors discovered at the University of California

March 4, 2022

Abm Therapeutics identifies new AXL/PAK1/c-KIT/RET/MAP4K1 inhibitors

March 4, 2022

Clarity Pharmaceuticals describes new radiopharmaceuticals

March 4, 2022

RedCloud cleared to enter clinic with next-generation EGFR inhibitor H-002 for NSCLC

March 3, 2022

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 2, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
CINP 2026: organoids reveal autism and addiction mechanisms
BioWorld Science
At the 2026 World Congress of Neuropsychopharmacology (CINP), held in Glasgow June 26-29, 2026, researchers from Japan’s National Center of Neurology and...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Reunion Neuroscience reports new 5-HT2A partial agonists and/or 5-HT2B antagonists
BioWorld Science
Reunion Neuroscience Inc. has identified new 5-HT2A receptor partial agonists and/or 5-HT2B receptor antagonists potentially useful for the treatment of...